See the published version of this preprint at World Journal of Surgical Oncology.
This is a preprint, a preliminary version of a manuscript that has not completed peer review at a journal. Research Square does not conduct peer review prior to posting preprints. The posting of a preprint on this server should not be interpreted as an endorsement of its validity or suitability for dissemination as established information or for guiding clinical practice.
Learn more about In Review
A new preprint design is coming!
We have improved readability, clarity, accessibility, and opportunities for engagement.
Research Article
Jingyu Xu
First Teaching Hospital of Tianjin University of Traditional Chinese Medicine
Corresponding Author
ORCiD: https://orcid.org/0000-0001-6004-2956
License:
This work is licensed under a CC BY 4.0 License. Read Full License
Objective: Regulation of single nucleotide polymorphisms (SNP) in micro-RNA ( miRNA) on the host cells may be one of the most important factors influencing the occurrence of cervical cancer based on the prevalence of HPV infection and the development of cervical cancer. In order to explore the contribution of miRNA polymorphism to the occurrence and development of cervical cancer, we conducted an analytical study.
Methods: We selected the polymorphisms of three widely studied miRNAs (miRNA-146a rs2910164, miRNA-499 rs3746444 and miRNA-196a2 rs11614913). Then we conducted a meta-analysis (for the first time) to investigate their susceptibility to cervical cancer. Case control studies on the correlation between these three miRNAs and cervical cancer susceptibility were investigated by searching on from Pubmed, The Cochrane Library, Embase, CBM, CNKI, Wanfang database and VIP database. Basic characteristics were recorded and meta-analysis of the case studies was performed using STATA 15.1 software.
Results: The miRNA-146a rs2910164 mutation significantly reduced the risk of cervical cancer in both recessive model (OR= 0.804, 95%CI= 0.652-0.992, P= 0.042；CC vs. CG+GG) and allelic model (OR= 0.845, 95%CI= 0.721-0.991, P= 0.038；C vs. G). There was no significant correlation between miRNA -499 rs3746444 and the risk of cervical cancer. The miRNA -196a2 rs11614913 mutation was significantly associated with a reduced risk of cervical cancer in homozygous model (OR= 0.641, 95%CI= 0.447-0.919, P= 0.016；TT vs. CC), dominant model (OR= 0.795, 95%CI= 0.636-0.994, P= 0.045；CT+TT vs. CC), recessive model (OR= 0.698, 95%CI= 0.532-0.917, P= 0.01；TT vs. CC+CT), and allelic models (OR= 0.783, 95%CI= 0.643-0.954, P= 0.015；T vs. C).
Conclusion: In summary, this meta-analysis shows that the mutant genotypes of miRNA -146a rs2910164 and miRNA -196a2 rs11614913 are associated with a reduced risk of cervical cancer. Therefore, they may be two gene regulatory points for the prevention of cervical cancer.
Keywords
micro-RNA, Single nucleotide polymorphism, cervical cancer, meta-analysis
Figure 1
Figure 2
Figure 3
This is a list of supplementary files associated with this preprint. Click to download.
- Table.S1ThePRISMAChecklist.doc
Supplementary Materials Table S1: the PRISMA checklist.
Loading...
Badges
Prescreen
This manuscript passed our Prescreen assessment
Complete author information
Appropriate declaration statements
Potential risks to human health
Prescreen
Peer Review Timeline
CURRENT STATUS: Published
View the published article at World Journal of Surgical Oncology.
No community comments so far
Editorial decision: Major Revision
On 24 Oct, 2021
Reviewer #3 agreed
On 04 Oct, 2021
Review #1 received
Received 09 Sep, 2021
Reviews received
Received 02 Sep, 2021
Reviewer #2 agreed
On 01 Sep, 2021
Editor assigned
On 01 Sep, 2021
Reviewers invited
Invitations sent on 01 Sep, 2021
Reviewer #1 agreed
On 01 Sep, 2021
Submission checks complete
On 31 Aug, 2021
Editor invited
On 31 Aug, 2021
First submitted
On 11 Aug, 2021
Version (no preprint)
Posted 22 Jul, 2021
Editorial decision: Reject with resubmission & Reject without review
On 22 Jul, 2021
Reviewer #2 agreed
On 19 Jul, 2021
Review #2 received
Received 19 Jul, 2021
Reviewer #1 agreed
On 16 Jul, 2021
Review #1 received
Received 16 Jul, 2021
Reviewers invited
Invitations sent on 15 Jul, 2021
Editor assigned
On 13 Jul, 2021
Submission checks complete
On 13 Jul, 2021
Editor invited
On 13 Jul, 2021
Version 1
Posted 14 Jun, 2021
No comments provided
Review #2 received
Received 04 Jul, 2021
Review #1 received
Received 20 Jun, 2021
Reviewer #2 agreed
On 19 Jun, 2021
Reviews received
Received 09 Jun, 2021
Reviewers invited
Invitations sent on 09 Jun, 2021
Reviewer #1 agreed
On 08 Jun, 2021
Editor assigned
On 06 Jun, 2021
Submission checks complete
On 05 Jun, 2021
Editor invited
On 05 Jun, 2021
First submitted
On 28 May, 2021
Metrics
Comments: 0
PDF Downloads: ...
HTML Views: ...
Learn more about our company.
A new preprint design is coming!
We have improved readability, clarity, accessibility, and opportunities for engagement.
See the published version of this preprint at World Journal of Surgical Oncology.
This is a preprint, a preliminary version of a manuscript that has not completed peer review at a journal. Research Square does not conduct peer review prior to posting preprints. The posting of a preprint on this server should not be interpreted as an endorsement of its validity or suitability for dissemination as established information or for guiding clinical practice.
Learn more about In Review
Research Article
Jingyu Xu
First Teaching Hospital of Tianjin University of Traditional Chinese Medicine
Corresponding Author
ORCiD: https://orcid.org/0000-0001-6004-2956
Badges
Prescreen
This manuscript passed our Prescreen assessment
Complete author information
Appropriate declaration statements
Potential risks to human health
Prescreen
Peer Review Timeline
CURRENT STATUS: Published
View the published article at World Journal of Surgical Oncology.
No community comments so far
Editorial decision: Major Revision
On 24 Oct, 2021
Reviewer #3 agreed
On 04 Oct, 2021
Review #1 received
Received 09 Sep, 2021
Reviews received
Received 02 Sep, 2021
Reviewer #2 agreed
On 01 Sep, 2021
Editor assigned
On 01 Sep, 2021
Reviewers invited
Invitations sent on 01 Sep, 2021
Reviewer #1 agreed
On 01 Sep, 2021
Submission checks complete
On 31 Aug, 2021
Editor invited
On 31 Aug, 2021
First submitted
On 11 Aug, 2021
Version (no preprint)
Posted 22 Jul, 2021
Editorial decision: Reject with resubmission & Reject without review
On 22 Jul, 2021
Reviewer #2 agreed
On 19 Jul, 2021
Review #2 received
Received 19 Jul, 2021
Reviewer #1 agreed
On 16 Jul, 2021
Review #1 received
Received 16 Jul, 2021
Reviewers invited
Invitations sent on 15 Jul, 2021
Editor assigned
On 13 Jul, 2021
Submission checks complete
On 13 Jul, 2021
Editor invited
On 13 Jul, 2021
Version 1
Posted 14 Jun, 2021
No comments provided
Review #2 received
Received 04 Jul, 2021
Review #1 received
Received 20 Jun, 2021
Reviewer #2 agreed
On 19 Jun, 2021
Reviews received
Received 09 Jun, 2021
Reviewers invited
Invitations sent on 09 Jun, 2021
Reviewer #1 agreed
On 08 Jun, 2021
Editor assigned
On 06 Jun, 2021
Submission checks complete
On 05 Jun, 2021
Editor invited
On 05 Jun, 2021
First submitted
On 28 May, 2021
Metrics
Comments: 0
PDF Downloads: ...
HTML Views: ...
License:
This work is licensed under a CC BY 4.0 License. Read Full License
View the published article at World Journal of Surgical Oncology.
Objective: Regulation of single nucleotide polymorphisms (SNP) in micro-RNA ( miRNA) on the host cells may be one of the most important factors influencing the occurrence of cervical cancer based on the prevalence of HPV infection and the development of cervical cancer. In order to explore the contribution of miRNA polymorphism to the occurrence and development of cervical cancer, we conducted an analytical study.
Methods: We selected the polymorphisms of three widely studied miRNAs (miRNA-146a rs2910164, miRNA-499 rs3746444 and miRNA-196a2 rs11614913). Then we conducted a meta-analysis (for the first time) to investigate their susceptibility to cervical cancer. Case control studies on the correlation between these three miRNAs and cervical cancer susceptibility were investigated by searching on from Pubmed, The Cochrane Library, Embase, CBM, CNKI, Wanfang database and VIP database. Basic characteristics were recorded and meta-analysis of the case studies was performed using STATA 15.1 software.
Results: The miRNA-146a rs2910164 mutation significantly reduced the risk of cervical cancer in both recessive model (OR= 0.804, 95%CI= 0.652-0.992, P= 0.042；CC vs. CG+GG) and allelic model (OR= 0.845, 95%CI= 0.721-0.991, P= 0.038；C vs. G). There was no significant correlation between miRNA -499 rs3746444 and the risk of cervical cancer. The miRNA -196a2 rs11614913 mutation was significantly associated with a reduced risk of cervical cancer in homozygous model (OR= 0.641, 95%CI= 0.447-0.919, P= 0.016；TT vs. CC), dominant model (OR= 0.795, 95%CI= 0.636-0.994, P= 0.045；CT+TT vs. CC), recessive model (OR= 0.698, 95%CI= 0.532-0.917, P= 0.01；TT vs. CC+CT), and allelic models (OR= 0.783, 95%CI= 0.643-0.954, P= 0.015；T vs. C).
Conclusion: In summary, this meta-analysis shows that the mutant genotypes of miRNA -146a rs2910164 and miRNA -196a2 rs11614913 are associated with a reduced risk of cervical cancer. Therefore, they may be two gene regulatory points for the prevention of cervical cancer.
Figure 1
Figure 2
Figure 3
This is a list of supplementary files associated with this preprint. Click to download.
- Table.S1ThePRISMAChecklist.doc
Supplementary Materials Table S1: the PRISMA checklist.
Loading...